Androgen deprivation therapy-associated vasomotor symptoms

Asian Journal of Andrology

Volumn 14, Issue 2, 2012, Pages 193-197

  Jones, Jason M ^a   Kohli, Manish ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

Author keywords

hot flashes; vandrogen deprivation therapy; vasomotor symptoms

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; BICALUTAMIDE; CITALOPRAM; CLONIDINE; CYPROTERONE ACETATE; DESVENLAFAXINE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; FLUOXETINE; GABAPENTIN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PAROXETINE; PLACEBO; PREGABALIN; SERTRALINE; VENLAFAXINE;

ACUPUNCTURE; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; BEHAVIOR CHANGE; BLOATING; CANCER GROWTH; COGNITIVE DEFECT; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECODYNIA; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPNOSIS; INSOMNIA; LOW DRUG DOSE; MASTALGIA; METASTASIS; MUSCLE WEAKNESS; NAUSEA; NEUROPATHIC PAIN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STELLATE GANGLION BLOCK; THROMBOEMBOLISM; THROMBOGENICITY; VASOMOTOR DISORDER; VOMITING; WEIGHT GAIN; XEROSTOMIA; YOGA;

AMINES; ANDROGEN ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; MALE; PROSTATIC NEOPLASMS; VASOMOTOR SYSTEM;

EID: 84863393685     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.101     Document Type: Review

References (67)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2011; 363: 1822-32.
3. SEER Stat Fact Sheets: Prostate. Bethesda, MD: National Cancer Institute; 2010.
4. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS et al. Estrogenic side effects of androgen deprivation therapy. Rev Urol 2007; 9: 163-80.
5. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003; 8: 474-87. (Pubitemid 37238876)
6. Huggins C, Hodges C. Studies on prosate cancer. Effect of castration, estrogen, and adrogen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
7. Quella S, Loprinzi CL, Dose AM. A qualitative approach to defining "hot flashes" in men. Urol Nurs 1994; 14: 155-8.
8. Loprinzi CL, Sherry L. Hot flushes: mostly sex neutral? Lancet Oncol 2010; 11: 107-8.
9. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994; 152: 1170-3. (Pubitemid 24283460)
10. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77: 1207-18. (Pubitemid 35266369)
11. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101: 337-45. (Pubitemid 36170136)
12. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009; 20: 542-9.
13. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 818-24. (Pubitemid 41557381)
14. Reddy SY, Warner H, Guttuso T Jr, Messing S, DigrazioWet al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41-8. (Pubitemid 44336843)
15. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347-52. (Pubitemid 24233853)
16. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147-54.
17. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006; 24: 1409-14. (Pubitemid 46622006)
18. Atala A, Amin M, Harty JI. Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology 1992; 39: 108-10.
19. Miller JI, Ahmann FR. Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology 1992; 40: 499-502. (Pubitemid 23003192)
20. Smith JA Jr. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. J Urol 1994; 152: 132-4. (Pubitemid 24175719)
21. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55: 97-101. (Pubitemid 30050765)
22. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82: 1784-8. (Pubitemid 28208931)
23. Goodwin JW, Green SJ, Moinpour CM, Bearden JD 3rd, Giguere JK et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 2008; 26: 1650-6.
24. Bertelli G, Venturini M, del Mastro L, Bergaglio M, Sismondi P et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13: 883-8. (Pubitemid 34752683)
25. Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 2005; 174: 642-5. (Pubitemid 40981622)
26. Sartor O, Eastham JA. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 1999; 92: 415-6. (Pubitemid 29197497)
27. Burch PA, Loprinzi CL. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate. J Clin Oncol 1999; 17: 1087-8. (Pubitemid 29109346)
28. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000; 54: 2161-3. (Pubitemid 30397222)
29. Loprinzi C, Barton D, Sloan J, Zahasky KM, Smith D et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77: 1155-63.
30. Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study-NCCTG Trial N00CB. J Support Oncol 2010; 8: 128-32.
31. Loprinzi CL, Qin R, Baclueva EP, Flynn KA, Rowland KM Jr et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2009; 28: 641-7.
32. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377-81. (Pubitemid 28309031)
33. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ et al. A pilot trial assessing the efficacy of paroxetine hydrochloride in controlling hot flashes. Breast Cancer Res Treat 1997; 46: 23-113.
34. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059-63. (Pubitemid 32009821)
35. Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009; 27: 2831-7.
36. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578-83. (Pubitemid 34260538)
37. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289: 2827-34. (Pubitemid 37430118)
38. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919-30.
39. Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA et al. Phase III, placebocontrolled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28: 3278-83.
40. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200: 172.e1-10.
41. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111: 77-87.
42. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999; 162: 98-102. (Pubitemid 29420889)
43. Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004; 79: 1247-51. (Pubitemid 39299067)
44. Naoe M, Ogawa Y, Shichijo T, Fuji K, Fukagai T et al. Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 275-8. (Pubitemid 44334701)
45. Roth AJ, Scher HI. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 1998; 7: 129-32. (Pubitemid 28197883)
46. Carpenter LA, Loprinzi C, Flynn PJ, Atheron P, Barton D et al. Pilot evaluation of citalopram for alleviation of hot flashes in women with inadequate hot flash control with venlafaxine. J Clin Oncol 2005; 23: 8061.
47. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a nonhormonal medication. Br Med J 1974; 1: 409-12.
48. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982; 60: 583-6. (Pubitemid 12037356)
49. Schindler AE, Muller D, Keller E, Goser R, Runkel F. Studies with clonidine (dixarit) in menopausal women. Arch Gynecol 1979; 227: 341-7. (Pubitemid 10164663)
50. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12: 155-8. (Pubitemid 24020635)
51. Loprinzi CL, Goldberg RM, O'Fallon JR, Quella SK, Miser AW et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol 1994; 151: 634-6. (Pubitemid 24054699)
52. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495-500. (Pubitemid 28135591)
53. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
54. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985; 22: 293-312. (Pubitemid 15127299)
55. North American Menopause S. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11: 11-33.
56. Conference NC. Acupuncture. JAMA 1998; 280: 1518-24.
57. Vincent A, Barton DL, Mandrekar JN, Cha SS, Zais T et al. Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause 2007; 14: 45-52. (Pubitemid 46084795)
58. Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: a systematic review. Menopause 2009; 16: 1065-73.
59. Hammar M, Frisk J, Grimas O, Hook M, Spetz AC et al. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 1999; 161: 853-6. (Pubitemid 29422382)
60. Beer TM, Benavides M, Emmons SL, Hayes M, Liu G et al. Acupuncture for hot flashes in patients with prostate cancer. Urology 2010; 76: 1182-8.
61. Lee MS, Kim KH, Shin BC, Choi SM, Ernst E. Acupuncture for treating hot flushes in men with prostate cancer: a systematic review. Support Care Cancer 2009; 17: 763-70.
62. Elkins G, Marcus J, Stearns V, Perfect M, Rajab MH et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008; 26: 5022-6.
63. Pachman DR, Barton D, Carns PE, Novotny PJ, Wolf S et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer 2011; 19: 941-7.
64. Lipov EG, Joshi JR, Sanders S, Wilcox K, Lipov S et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008; 9: 523-32.
65. Loprinzi CL, Barton DL, Carns PE. Stellate-ganglion block: a new treatment for hot flushes? Lancet Oncol 2008; 9: 506-7. (Pubitemid 351722576)
66. Lipov E, Lipov S, Stark JT. Stellate ganglion blockade provides relief from menopausal hot flashes: a case report series. J Womens Health (Larchmt) 2005; 14: 737-41. (Pubitemid 41645636)
67. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study.Menopause 2005; 12: 18-26. (Pubitemid 40204889)